Related Experiment Video
Updated: May 30, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
[Citrullinated proteins in rheumatoid arthritis]
Elizabeth Olivares Martínez1, Diego F Hernández Ramírez, Carlos A Núñez-Álvarez
1Laboratorio de Inmunología, Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México D.F., México.
Anti-citrullinated protein antibodies (ACPA) show high accuracy for diagnosing rheumatoid arthritis. These antibodies also predict disease severity, indicating a key role in rheumatoid arthritis pathogenesis.
Area of Science:
- Immunology
- Rheumatology
- Autoimmune Diseases
Background:
- Rheumatoid arthritis is an autoimmune disease impacting joints.
- It involves autoantibodies targeting various self-antigens.
- The multifactorial etiology of rheumatoid arthritis is complex.
Purpose of the Study:
- To highlight the diagnostic and prognostic significance of anti-citrullinated protein antibodies (ACPA) in rheumatoid arthritis.
- To explore the role of ACPA in rheumatoid arthritis pathogenesis.
Main Methods:
- Review of recent studies on ACPA in rheumatoid arthritis.
- Analysis of ACPA specificity and sensitivity for diagnosis.
- Evaluation of ACPA as a predictor of rheumatoid arthritis severity.
Main Results:
- ACPA demonstrate high specificity and sensitivity for rheumatoid arthritis diagnosis.
- ACPA levels correlate with disease severity in rheumatoid arthritis patients.
- ACPA are implicated in the underlying mechanisms of rheumatoid arthritis.
Conclusions:
- ACPA are valuable biomarkers for rheumatoid arthritis diagnosis.
- ACPA serve as important predictors of rheumatoid arthritis disease progression.
- Further research into ACPA's role in pathogenesis is warranted.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Rheumatic Heart Disease I: Introduction
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease III: Crohn's Disease
Inflammatory Bowel Disease II: Ulcerative Colitis
The JAK-STAT Signaling Pathway